Osteosarcoma survival rate & prognosis — what parents need to know

Osteosarcoma outcomes depend heavily on whether the cancer has spread at the time of diagnosis. For children with localised osteosarcoma — where the tumour is confined to the bone it started in and has not spread to the lungs or other sites — long-term survival rates with modern multimodal treatment are meaningfully better than they were even two decades ago. For children with metastatic osteosarcoma at diagnosis, the outlook is more challenging, though some children with lung-only spread who achieve complete surgical removal of all metastases can still do well.

The single most important prognostic factor, apart from spread, is how much the tumour cells die in response to pre-operative chemotherapy. Your child's oncologist will give you a personalised picture based on their specific findings — population statistics are a starting point, not a verdict.

The most important factors shaping osteosarcoma prognosis are: (1) whether the disease is localised or metastatic at diagnosis — spread to the lungs or other bones worsens the outlook significantly; (2) the histological response to pre-operative chemotherapy — a good response (90% or more tumour cell death, called good necrosis) is one of the strongest predictors of long-term survival; (3) the completeness of surgical resection — achieving clear margins around the tumour is critical; (4) the location of the tumour — osteosarcoma of the axial skeleton, such as the pelvis or spine, is harder to remove completely than limb tumours; and (5) the presence of skip lesions or pathological fracture.

These factors together guide the oncology team's treatment decisions and intensity.

After a child receives neoadjuvant (pre-operative) chemotherapy, the surgeon removes the tumour and the pathologist examines it under a microscope to measure how many cancer cells have been killed. If 90% or more of the tumour cells are dead — a result called "good necrosis" or a good histological response — this is one of the strongest favourable prognostic signs in osteosarcoma. It suggests the tumour was highly sensitive to the chemotherapy used, and that post-operative treatment is more likely to work too.

Children with a poor response (less than 90% tumour cell death) may be offered a change to their post-operative chemotherapy protocol to compensate. The necrosis percentage is reported in the final pathology report after surgery.

In most children treated at experienced centres, limb-salvage surgery — removing the tumour while keeping the arm or leg — is now achievable. This is made possible by advances in pre-operative chemotherapy (which shrinks the tumour and defines a margin), surgical techniques, and custom prosthetic implants or bone grafting. The decision between limb-salvage and amputation depends on whether clear surgical margins can be achieved while preserving a functional limb.

When limb-salvage is performed with proper margins, survival outcomes are equivalent to amputation. Limb function after surgery depends on the location and extent of the tumour and the type of reconstruction used. Your child's orthopaedic oncologist will discuss which option is most appropriate for their specific tumour.

Yes — relapse is a recognised risk in osteosarcoma, most often occurring within two to three years of completing treatment. The lungs are the most common site of recurrence, which is why chest CT scans are performed every two to three months during the first two years of follow-up. Relapse in the original bone site (local recurrence) or at a new bone site also occurs.

If osteosarcoma returns, treatment options depend on the timing, site, and extent of relapse, and on what treatment the child has already received. Complete surgical removal of all recurrent disease — particularly isolated lung metastases — offers the best chance of a second remission. A tumour board second-opinion review is strongly advised at the time of any relapse.

Follow-up after osteosarcoma treatment is intensive for the first few years. Chest CT scans to check for lung metastases are typically performed every two to three months for the first two years, then less frequently in years three to five. X-rays or MRI of the primary tumour site are done at each visit to detect any local recurrence. Blood tests check organ function after chemotherapy.

As years pass and no recurrence is detected, follow-up intervals lengthen. Long-term survivors are also monitored for late effects of chemotherapy and radiation, including heart function, hearing, and bone health around prosthetic implants. Completing every scheduled follow-up appointment is as important as the treatment itself.